Want to see EW full AI Analyst Report?
EW Stock Chart & Stats
$80.99
$0.80(1.09%)
At close: 4:00 PM EST
$80.99
$0.80(1.09%)
Day’s Range― - ―
52-Week Range$72.30 - $89.60
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.95M
Market Cap
$54.34B
Enterprise Value$48.17B
Total Cash (Recent Filing)$3.67B
Total Debt (Recent Filing)$702.90M
Price to Earnings (P/E)49.9
Beta0.57
Next Earnings
Jul 23, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding575,800,000
10 Day Avg. Volume4,692,429
30 Day Avg. Volume4,946,967
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)4.82
Price to Sales (P/S)8.22
P/FCF Ratio37.34
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue7.64
Enterprise Value/Gross Profit9.79
Enterprise Value/Ebitda33.90
Forecast
1Y Price Target
$99.57Price Target Upside22.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)3.01
Revenue Forecast (FY)$6.76B
Bulls Say, Bears Say
Bulls Say
High Profitability & MarginsEdwards' very high gross and healthy operating/net margins reflect durable pricing power and a favorable product mix (high-margin valves and consumables). Sustained margin headroom supports long-term R&D, commercialization investment and resilience to reimbursement pressure over the next 2–6 months.
Conservative Balance SheetExtremely low leverage provides durable financial flexibility: capacity for targeted M&A, capex or share programs without stressing liquidity. That conservative structure reduces solvency risk amid reimbursement or procedure-volume variability and supports multi-quarter strategic optionality.
Regulatory Tailwind For Core TAVR BusinessA CMS proposal to broaden national TAVR coverage is a structural demand driver: broader reimbursement and clearer criteria can materially expand the addressable patient pool, lower adoption barriers and sustain procedure volumes over quarters, strengthening Edwards' core transcatheter franchise.
Bears Say
Subdued Revenue GrowthRevenue expansion has been modest, limiting operating leverage and the pace at which profit growth translates to absolute earnings. Without material share gains, new indications, or faster adoption, muted top-line momentum constrains sustainable EPS growth and investment returns over the medium term.
Weakened Cash ConversionDeclining FCF and sub‑100% cash conversion reduce internal funding for R&D, capital projects and shareholder returns. If conversion remains below historical norms, the company may face tougher capital allocation choices and less buffer against margin or volume shocks in coming quarters.
Expanded Equity Incentive Plan; Dilution RiskA materially larger equity award pool helps recruit and retain key talent but raises potential share issuance and EPS dilution over time. Heavy use of the expanded pool could limit per‑share earnings growth and act as a persistent overhang on capital allocation if awards are sizable.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences Corp.’s price range in the past 12 months?
Edwards Lifesciences Corp. lowest stock price was $72.30 and its highest was $89.60 in the past 12 months.
What is Edwards Lifesciences Corp.’s market cap?
Edwards Lifesciences Corp.’s market cap is $54.34B.
When is Edwards Lifesciences Corp.’s upcoming earnings report date?
Edwards Lifesciences Corp.’s upcoming earnings report date is Jul 23, 2026 which is in 18 days.
How were Edwards Lifesciences Corp.’s earnings last quarter?
Edwards Lifesciences Corp. released its earnings results on Apr 23, 2026. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.729 by $0.051.
Is Edwards Lifesciences Corp. overvalued?
According to Wall Street analysts Edwards Lifesciences Corp.’s price is currently Undervalued.
Does Edwards Lifesciences Corp. pay dividends?
Edwards Lifesciences Corp. does not currently pay dividends.
What is Edwards Lifesciences Corp.’s EPS estimate?
Edwards Lifesciences Corp.’s EPS estimate is 0.74.
How many shares outstanding does Edwards Lifesciences Corp. have?
Edwards Lifesciences Corp. has 575,800,000 shares outstanding.
What happened to Edwards Lifesciences Corp.’s price movement after its last earnings report?
Edwards Lifesciences Corp. reported an EPS of $0.78 in its last earnings report, beating expectations of $0.729. Following the earnings report the stock price went up 5.557%.
Which hedge fund is a major shareholder of Edwards Lifesciences Corp.?
Currently, no hedge funds are holding shares in EW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edwards Lifesciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.57 (22.94% Upside)
$99.57 (22.94% Upside)
Blogger Sentiment
Bullish
EW Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.7%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.52%
12-Months-Change
Fundamentals
Return on Equity
10.55%
Trailing 12-Months
Asset Growth
2.30%
Trailing 12-Months
Company Description
Edwards Lifesciences Corp.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
EW Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a broadly positive outlook: the company delivered strong top‑line growth (Q4 +11.6%, FY +10.7%), robust TAVR and TMTT momentum, and reiterated confident 2026 guidance (8%–10% sales growth; EPS $2.90–$3.05). Key positives include compelling long‑term clinical evidence, successful product launches (SAPIEN M3, NextGen PASCAL), margin discipline and a healthy balance sheet. Near‑term headwinds are primarily deliberate investments in patient access and field resources (driving higher SG&A), one‑time GAAP charges (GennaValve/litigation), an elevated tax rate in the quarter, and distributor inventory adjustments that modestly impacted surgical sales. Management frames the incremental spending as strategic and expects margin expansion over time. Overall, the positive operational and strategic catalysts outweigh the one‑time and timing‑related negatives.View all EW earnings summariesEW Net sales Breakdown
73.96% Transcatheter Aortic Valve Replacement
9.07% Transcatheter Mitral and Tricuspid Therapies
16.96% Surgical Structural Heart
EW Stock 12 Month Forecast
Average Price Target
$99.57
▲(22.94% Upside)
Technical Analysis
Ownership Overview
0.22% Insiders
25.50% Mutual Funds
0.08% Other Institutional Investors
47.84% Public Companies and
Individual Investors